Abstract:International Journal of Stroke, Ahead of Print. Rationale:Clinical outcomes in acute ischemic stroke due to medium vessel occlusion (MeVO) are often poor when treated with best medical management. Data from non-randomized studies suggest that endovascular treatment (EVT) may improve outcomes in MeVO stroke, but randomized data on potential benefits and risks are hitherto lacking. Thus, there is insufficient evidence to guide EVT decision-making in MeVO stroke.Aims:The primary aim of the ESCAPE-MeVO trial is to demonstrate that acute, rapid EVT in patients with acute ischemic stroke due to MeVO results in better clinical outcomes compared to best medical management. Secondary outcomes are to demonstrate the safety of EVT, its impact on self-reported health-related quality of life, and cost-effectiveness.Sample size estimates:Based on previously published data, we estimate a sample size of 500 subjects to achieve a power of 85% with a two-sided alpha of 0.05. To account for potential loss to follow-up, 530 subjects will be recruited.Methods and design:ESCAPE-MeVO is a multicenter, prospective, randomized, open-label study with blinded endpoint evaluation (PROBE design), clinicaltrials.gov: NCT05151172. Subjects with acute ischemic stroke due to MeVO meeting the trial eligibility criteria will be allocated in a 1:1 ratio to best medical care plus EVT versus best medical care only. Patients will be screened only at comprehensive stroke centers to determine if they are eligible for the trial, regardless of whether they were previously treated at a primary care center. Key eligibility criteria are (1) acute ischemic stroke due to MeVO that is clinically and technically eligible for EVT, (2) last-known well within the last 12 h, (3) National Institutes of Health Stroke Scale > 5 or 3–5 with disabling deficit, (4) high likelihood of salvageable tissue on non-invasive neuroimaging.Study outcomes:The primary outcome is the modified Rankin scale 90 days after randomization (shift analysis), whereby modified Rankin Score 5 and 6 will be collapsed into one category. Secondary outcomes include dichotomizations of the modified Rankin Score at 90 days, 24 h National Institutes of Health Stroke Score, difference between 24 h and baseline National Institutes of Health Stroke Score, mortality at 90 days, health-related quality of life (EQ-5D-5 L), Lawton scale of instrumental activities of daily living score, reperfusion quality (MeVO expanded Thrombolysis in Cerebral Infarction Score) and infarct volume at 24 h, and cost-effectiveness of endovascular recanalization. Safety outcomes include symptomatic and asymptomatic intracranial hemorrhage and procedural complications.Discussion:The ESCAPE-MeVO trial will demonstrate the effect of endovascular thrombectomy in addition to best medical management vis-à-vis best medical management in patients with acute ischemic stroke due to MeVO and provide data for evidence-based treatment decision-making in acute MeVO stroke.Data access statement:The raw data discussed in this mansucript will be made available by the corresponding author upon reasonable request.

Benefit of endovascular treatment for primary versus secondary medium vessel occlusion: A multi‐center experience

The Safety and Efficacy of Endovascular Treatment in Acute Ischemic Stroke Patients Caused by Large-Vessel Occlusion with Different Etiologies of Stroke: Data from ANGEL-ACT Registry

Endovascular treatment for acute basilar artery occlusion due to different stroke etiologies of large artery atherosclerosis and cardioembolism.

Endovascular Thrombectomy with or Without Intravenous Alteplase in Acute Stroke

Endovascular Treatment for Minor Acute Ischemic Strokes with Large Vessel Occlusion

Endovascular Treatment Achieves Better Outcomes Than Best Medical Management in Patients with M2 Occlusion and High Stroke Severity: a Meta-Analysis

Outcomes and differences by occluded vessel after endovascular thrombectomy for isolated medium vessel occlusions

A comparison of endovascular therapy and medical management in patients with large vessel occlusion mild stroke treated between 2015 and 2023: a systematic review and meta-analysis

Endovascular treatment to improve outcomes for medium vessel occlusions: The ESCAPE-MeVO trial

Endovascular Treatment or General Treatment: How Should Acute Ischemic Stroke Patients Choose to Benefit from Them the Most?

Endovascular therapy for acute ischemic stroke with distal medium vessel occlusion: a systematic review and meta-analysis

Endovascular therapy versus best medical management in distal medium middle cerebral artery acute ischaemic stroke: a multinational multicentre propensity score-matched study

Endovascular Treatment of Medium Vessel Occlusion Stroke

Comparing Outcomes of Thrombectomy Versus Intravenous Thrombolysis Based on Middle Cerebral Artery M2 Occlusion Features

Endovascular treatment for acute M2 occlusion stroke within 6 hours-a retrospective real-world evidence

Endovascular Thrombectomy Versus Medical Management in Isolated M2 Occlusions: Pooled Patient‐Level Analysis from the EXTEND‐IA Trials, INSPIRE, and SELECT Studies

Outcome of endovascular treatment in acute basilar artery occlusion with National Institutes of Health Stroke Scale score 10–19

Endovascular treatment versus standard medical treatment in patients with established large infarct: a cohort study

A review of endovascular treatment for medium vessel occlusion stroke

Tenecteplase Versus Alteplase in Medium Vessel Occlusion Ischemic Stroke: A Secondary Analysis of the Alteplase Compared to Tenecteplase Randomized Trial

Endovascular Therapy versus Medical Management for Acute Ischemic Stroke with Large Infarct Core: systematic review and meta-analysis of randomized controlled trials